Sentiment-Signal
29,9
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
23.2
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Unternehmen & Branche
| Name | Zai Lab Ltd |
|---|---|
| Ticker | ZLAB |
| CIK | 0001704292 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 98887Q104 |
|---|---|
| ISIN | US98887Q1040 |
| Typ | ADR |
| Marktkapitalisierung | 2,78 Mrd. USD |
| Beta | 0,86 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 460,156,000 | -175,537,000 | -0.16 | 1,172,384,000 | 715,500,000 |
| 2025-09-30 | 10-Q | 116,095,000 | -35,963,000 | -0.03 | 1,158,940,000 | 759,945,000 |
| 2025-06-30 | 10-Q | 109,977,000 | -40,727,000 | -0.04 | 1,164,101,000 | 791,735,000 |
| 2025-03-31 | 10-Q | 106,487,000 | -48,438,000 | -0.04 | 1,173,330,000 | 810,753,000 |
| 2024-12-31 | 10-K | 398,988,000 | -257,103,000 | -0.26 | 1,185,753,000 | 840,898,000 |
| 2024-09-30 | 10-Q | 102,265,000 | -41,671,000 | -0.04 | 985,346,000 | 667,669,000 |
| 2024-06-30 | 10-Q | 100,504,000 | -80,277,000 | -0.08 | 987,368,000 | 704,179,000 |
| 2024-03-31 | 10-Q | 87,149,000 | -53,471,000 | -0.05 | 988,437,000 | 762,169,000 |
| 2023-12-31 | 10-K | 266,719,000 | -334,620,000 | -0.35 | 1,036,295,000 | 796,118,000 |
| 2023-09-30 | 10-Q | 69,228,000 | -69,152,000 | -0.07 | 1,043,694,000 | 880,979,000 |
| 2023-06-30 | 10-Q | 68,864,000 | -120,895,000 | -0.13 | 1,106,373,000 | 932,314,000 |
| 2023-03-31 | 10-Q | 62,797,000 | -49,144,000 | -0.05 | 1,170,074,000 | 1,001,242,000 |
| 2022-12-31 | 10-K | 215,040,000 | -443,286,000 | -0.46 | 1,220,140,000 | 1,045,595,000 |
| 2022-09-30 | 10-Q | 57,540,000 | -161,190,000 | -0.17 | 1,298,514,000 | 1,105,869,000 |
| 2022-06-30 | 10-Q | 48,176,000 | -137,933,000 | -0.14 | 1,418,777,000 | 1,212,165,000 |
| 2022-03-31 | 10-Q | 46,724,000 | -82,394,000 | -0.09 | 1,500,915,000 | 1,308,008,000 |
| 2021-12-31 | 10-K | 144,312,000 | -211,825,000 | -0.76 | 1,609,956,000 | 1,379,956,000 |
| 2021-09-30 | 10-K | 43,103,000 | -96,412,000 | |||
| 2021-09-30 | 10-Q | 43,103,000 | -96,412,000 | -0.10 | 1,728,079,000 | 1,587,930,000 |
| 2021-06-30 | 10-K | 36,935,000 | -163,324,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 6,959,032 | 0 | 6,959,032 | 122,757,324 | Neu | +100,0% | |
| Frazier Life Sciences Management, L.P. | 1,902,320 | 0 | 1,902,320 | 33,556,925 | Neu | +100,0% | |
| Clearbridge Investments, LLC | 1,808,035 | 0 | 1,808,035 | 31,893,740 | Neu | +100,0% | |
| UBS Group AG | 1,782,252 | 0 | 1,782,252 | 31,438,925 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1,749,546 | 0 | 1,749,546 | 30,861,992 | Neu | +100,0% | |
| FMR LLC | 1,440,406 | 0 | 1,440,406 | 25,408,762 | Neu | +100,0% | |
| BAMCO INC /NY/ | 1,418,005 | 0 | 1,418,005 | 25,013,608 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 1,246,520 | 0 | 1,246,520 | 21,988,613 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 752,858 | 0 | 752,858 | 13,280,417 | Neu | +100,0% | |
| BlackRock, Inc. | 635,213 | 0 | 635,213 | 11,205,157 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 577,562 | 0 | 577,562 | 10,188,194 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 388,769 | 0 | 388,769 | 6,857,886 | Neu | +100,0% | |
| Legal & General Group Plc | 387,800 | 0 | 387,800 | 6,842,649 | Neu | +100,0% | |
| Walleye Capital LLC | 373,399 | 0 | 373,399 | 6,586,758 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 293,703 | 0 | 293,703 | 5,180,921 | Neu | +100,0% | |
| MORGAN STANLEY | 289,705 | 0 | 289,705 | 5,110,397 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 238,609 | 0 | 238,609 | 4,209,063 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 231,802 | 0 | 231,802 | 4,088,987 | Neu | +100,0% | |
| XY Capital Ltd | 202,304 | 0 | 202,304 | 3,568,643 | Neu | +100,0% | |
| SUPERSTRING CAPITAL MANAGEMENT LP | 196,853 | 0 | 196,853 | 3,472,487 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 181,133 | 0 | 181,133 | 3,195,186 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 173,946 | 0 | 173,946 | 3,068,352 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 149,434 | 0 | 149,434 | 2,636,016 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 148,195 | 0 | 148,195 | 2,614,160 | Neu | +100,0% | |
| STATE STREET CORP | 136,428 | 0 | 136,428 | 2,406,590 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 107,651 | 0 | 107,651 | 1,898,964 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 101,782 | 0 | 101,782 | 1,795,434 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 96,442 | 0 | 96,442 | 1,701,237 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 93,140 | 0 | 93,140 | 1,642,990 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 92,837 | 0 | 92,837 | 1,637,637 | Neu | +100,0% | |
| Hudson Bay Capital Management LP | 90,000 | 0 | 90,000 | 1,587,600 | Neu | +100,0% | |
| Long Corridor Asset Management Ltd | 65,800 | 0 | 65,800 | 1,160,712 | Neu | +100,0% | |
| GROUP ONE TRADING LLC | 47,232 | 0 | 47,232 | 833,172 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 46,935 | 0 | 46,935 | 827,464 | Neu | +100,0% | |
| Schonfeld Strategic Advisors LLC | 40,005 | 0 | 40,005 | 705,687 | Neu | +100,0% | |
| Virtus Investment Advisers, LLC | 38,457 | 0 | 38,457 | 678,381 | Neu | +100,0% | |
| WealthPlan Investment Management, LLC | 36,761 | 0 | 36,761 | 648,464 | Neu | +100,0% | |
| MML INVESTORS SERVICES, LLC | 34,421 | 0 | 34,421 | 607,186 | Neu | +100,0% | |
| LPL Financial LLC | 31,114 | 0 | 31,114 | 548,851 | Neu | +100,0% | |
| DRW Securities, LLC | 30,862 | 0 | 30,862 | 544,405 | Neu | +100,0% | |
| Invesco Ltd. | 30,594 | 0 | 30,594 | 539,678 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 29,523 | 0 | 29,523 | 520,786 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 23,879 | 0 | 23,879 | 421,225 | Neu | +100,0% | |
| BANK OF MONTREAL /CAN/ | 22,099 | 0 | 22,099 | 389,827 | Neu | +100,0% | |
| US BANCORP \DE\ | 17,771 | 0 | 17,771 | 313,482 | Neu | +100,0% | |
| Marks Group Wealth Management, Inc | 16,278 | 0 | 16,278 | 287,144 | Neu | +100,0% | |
| Legacy Wealth Asset Management, LLC | 15,903 | 0 | 15,903 | 280,529 | Neu | +100,0% | |
| Headlands Technologies LLC | 15,846 | 0 | 15,846 | 279,523 | Neu | +100,0% | |
| IvyRock Asset Management (HK) Ltd | 14,979 | 0 | 14,979 | 264,230 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 14,757 | 0 | 14,757 | 260,000 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Edmondson Frazor Titus III | Officer, Chief Legal Officer | Open Market Sale | -4,194 | 20.39 | -85,515.66 | -19,4% | |
| 2026-04-02 | Smiley Joshua L | Officer, See Remarks | Open Market Sale | -9,614 | 20.39 | -196,029.46 | -44,4% | |
| 2026-04-02 | Chen Yajing | Officer, Chief Financial Officer | Open Market Sale | -5,199 | 20.39 | -106,007.61 | -24,0% | |
| 2026-04-02 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -5,576 | 20.39 | -113,694.64 | -25,7% | |
| 2026-04-02 | Amado Rafael | Officer, See Remarks | Open Market Sale | -9,910 | 20.39 | -202,064.90 | -45,7% | |
| 2026-03-17 | GAYNOR RICHARD | Director | Open Market Purchase | 1,731 | 18.91 | 32,733.21 | +7,4% | |
| 2026-03-13 | Amado Rafael | Officer, See Remarks | Open Market Sale | -2,957 | 18.63 | -55,083.00 | -12,5% | |
| 2026-03-13 | Edmondson Frazor Titus III | Officer, Chief Legal Officer | Open Market Sale | -1,281 | 18.63 | -23,862.47 | -5,4% | |
| 2026-03-13 | Smiley Joshua L | Officer, See Remarks | Open Market Sale | -1,966 | 18.63 | -36,622.65 | -8,3% | |
| 2026-03-13 | Chen Yajing | Officer, Chief Financial Officer | Open Market Sale | -1,703 | 18.63 | -31,723.48 | -7,2% | |
| 2026-03-11 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -1,067 | 19.08 | -20,362.63 | -4,6% | |
| 2026-03-09 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -50,000 | 19.03 | -951,465.00 | -215,3% | |
| 2026-03-06 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -50,000 | 19.42 | -970,935.00 | -219,7% | |
| 2026-03-05 | Edmondson Frazor Titus III | Officer, Chief Legal Officer | Open Market Sale | -15,569 | 19.06 | -296,745.14 | -67,2% | |
| 2026-03-05 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -50,000 | 19.22 | -961,055.00 | -217,5% | |
| 2026-03-04 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -35,710 | 19.32 | -689,831.50 | -156,1% | |
| 2026-03-04 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -14,290 | 18.78 | -268,321.90 | -60,7% | |
| 2026-03-03 | Amado Rafael | Officer, See Remarks | Open Market Sale | -10,000 | 17.38 | -173,800.00 | -39,3% | |
| 2025-12-31 | Amado Rafael | Officer, See Remarks | Open Market Sale | -10,787 | 17.43 | -188,038.98 | -42,6% | |
| 2025-12-16 | Edmondson Frazor Titus III | Officer, Chief Legal Officer | Open Market Sale | -8,651 | 17.14 | -148,278.14 | -33,6% | |
| 2025-11-21 | Edmondson Frazor Titus III | Officer, Chief Legal Officer | Open Market Sale | -14,328 | 19.78 | -283,407.84 | -64,1% | |
| 2025-11-03 | Chen Yajing | Officer, Chief Financial Officer | Open Market Sale | -240 | 26.83 | -6,439.44 | -1,5% | |
| 2025-10-02 | Chen Yajing | Officer, Chief Financial Officer | Open Market Sale | -456 | 34.25 | -15,616.63 | -3,5% | |
| 2025-09-10 | Smiley Joshua L | Officer, See Remarks | Open Market Purchase | 10,000 | 28.91 | 289,100.00 | +65,4% | |
| 2025-08-18 | Smiley Joshua L | Officer, See Remarks | Open Market Sale | -6,641 | 36.24 | -240,643.28 | -54,5% | |
| 2025-08-18 | Edmondson Frazor Titus III | Officer, Chief Legal Officer | Open Market Sale | -1,883 | 36.24 | -68,232.39 | -15,4% | |
| 2025-08-15 | Chen Yajing | Officer, Chief Financial Officer | Open Market Sale | -828 | 35.53 | -29,418.84 | -6,7% | |
| 2025-08-15 | Chen Yajing | Officer, Chief Financial Officer | Open Market Sale | -610 | 35.27 | -21,512.87 | -4,9% | |
| 2025-08-13 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -46,387 | 35.47 | -1,645,286.59 | -372,3% | |
| 2025-08-12 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -50,000 | 34.25 | -1,712,555.00 | -387,6% | |
| 2025-08-11 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -50,000 | 34.64 | -1,731,815.00 | -391,9% | |
| 2025-08-08 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -50,000 | 34.74 | -1,737,155.00 | -393,1% | |
| 2025-08-08 | Chen Yajing | Officer, Chief Financial Officer | Open Market Sale | -4,096 | 34.01 | -139,304.96 | -31,5% | |
| 2025-08-08 | Amado Rafael | Officer, See Remarks | Open Market Sale | -3,000 | 35.00 | -105,000.00 | -23,8% | |
| 2025-07-02 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -7,072 | 35.23 | -249,146.56 | -56,4% | |
| 2025-06-30 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -6,918 | 35.52 | -245,727.36 | -55,6% | |
| 2025-06-26 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -23,669 | 36.13 | -855,208.31 | -193,5% | |
| 2025-06-26 | Edmondson Frazor Titus III | Officer, Chief Legal Officer | Open Market Sale | -5,877 | 36.13 | -212,347.76 | -48,1% | |
| 2025-06-26 | Chen Yajing | Officer, Chief Financial Officer | Open Market Sale | -2,675 | 36.13 | -96,653.10 | -21,9% | |
| 2025-06-02 | Chen Yajing | Officer, Chief Financial Officer | Open Market Sale | -9,618 | 30.00 | -288,540.00 | -65,3% | |
| 2025-05-14 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -46,006 | 28.08 | -1,291,816.28 | -292,3% | |
| 2025-05-14 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -383 | 28.83 | -11,041.12 | -2,5% | |
| 2025-05-13 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -47,780 | 28.56 | -1,364,506.02 | -308,8% | |
| 2025-05-13 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -2,220 | 28.89 | -64,143.57 | -14,5% | |
| 2025-05-12 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -49,384 | 29.44 | -1,453,736.56 | -329,0% | |
| 2025-05-12 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -616 | 29.92 | -18,430.78 | -4,2% | |
| 2025-05-09 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -46,362 | 29.58 | -1,371,401.87 | -310,4% | |
| 2025-05-09 | Du Ying | Director, Officer, Chairperson & CEO | Open Market Sale | -3,638 | 30.16 | -109,738.45 | -24,8% |
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-03-31 | 14.250 | 17,85 | 254.363 |
| 2026-03-30 | 5.052 | 18,00 | 90.936 |
| 2026-03-27 | 60.611 | 17,51 | 1.061.299 |
| 2026-03-26 | 12.433 | 18,29 | 227.400 |
| 2026-03-25 | 110.350 | 17,47 | 1.927.814 |
| 2026-03-23 | 43.901 | 18,09 | 794.169 |
| 2026-03-20 | 168.321 | 18,61 | 3.132.454 |
| 2026-03-18 | 42.103 | 19,02 | 800.799 |
| 2026-03-17 | 84.237 | 19,06 | 1.605.557 |
| 2026-03-16 | 22.732 | 18,37 | 417.587 |
| 2026-03-13 | 4.755 | 18,87 | 89.727 |
| 2026-03-06 | 2.985 | 19,30 | 57.611 |
| 2026-03-05 | 1.174 | 19,27 | 22.623 |
| 2026-03-04 | 47.095 | 17,72 | 834.523 |
| 2026-03-03 | 42.405 | 18,42 | 781.100 |
| 2026-03-02 | 1.459 | 19,22 | 28.042 |
| 2026-02-27 | 2.997 | 19,69 | 59.011 |
| 2026-02-25 | 70 | 19,37 | 1.356 |
| 2026-02-23 | 21.309 | 20,04 | 427.032 |
| 2026-02-20 | 637 | 20,08 | 12.791 |
| 2026-02-19 | 48 | 20,18 | 969 |
| 2026-02-18 | 3.249 | 20,04 | 65.110 |
| 2026-02-17 | 521 | 20,03 | 10.436 |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| RTW INVESTMENTS, LP | 6,959,032 | 122,757,324 | 27.95 |
| Frazier Life Sciences Management, L.P. | 1,902,320 | 33,556,925 | 7.64 |
| Clearbridge Investments, LLC | 1,808,035 | 31,893,740 | 7.26 |
| UBS Group AG | 1,782,252 | 31,438,925 | 7.16 |
| CITADEL ADVISORS LLC | 1,749,546 | 30,861,992 | 7.03 |
| FMR LLC | 1,440,406 | 25,408,762 | 5.79 |
| BAMCO INC /NY/ | 1,418,005 | 25,013,608 | 5.70 |
| ADAR1 Capital Management, LLC | 1,246,520 | 21,988,613 | 5.01 |
| WELLINGTON MANAGEMENT GROUP LLP | 752,858 | 13,280,417 | 3.02 |
| BlackRock, Inc. | 635,213 | 11,205,157 | 2.55 |
| JANE STREET GROUP, LLC | 577,562 | 10,188,194 | 2.32 |
| BANK OF AMERICA CORP /DE/ | 388,769 | 6,857,886 | 1.56 |
| Legal & General Group Plc | 387,800 | 6,842,649 | 1.56 |
| Walleye Capital LLC | 373,399 | 6,586,758 | 1.50 |
| JPMORGAN CHASE & CO | 293,703 | 5,180,921 | 1.18 |
| MORGAN STANLEY | 289,705 | 5,110,397 | 1.16 |
| D. E. Shaw & Co., Inc. | 238,609 | 4,209,063 | 0.96 |
| MARSHALL WACE, LLP | 231,802 | 4,088,987 | 0.93 |
| XY Capital Ltd | 202,304 | 3,568,643 | 0.81 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 196,853 | 3,472,487 | 0.79 |